Lucid Diagnostics reports Q2 adjusted EPS (23c), consensus (32c)

“Lucid closed out a strong first half of 2023, with yet another quarter of double-digit EsoGuard test volume growth and major accomplishments on multiple strategic fronts, which we believe will drive substantial value in the coming quarters” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “Commercial execution underpinning the sustained test volume growth remained very strong, driven by steadily increasing per-seller productivity as well as expanding utilization of our satellite Lucid Test Center program and high-volume #CheckYourFoodTube testing events. The launch of our first mobile test unit and the execution of our first direct contract with an employer to offer EsoGuard testing as an employee benefit, reflect our relentless commitment to expanding EsoGuard access across all available channels.”